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Abstract 
Background 
Neuromodulatory medications (NMs), such as Amitriptyline, Carbamazepine, and 
Gabapentin are used as topical preparations for management of neuropathic 
orofacial pain (NOP) and have produced promising preliminary results. The aim of 
this study was to investigate the effects of three aforementioned NMs on cell lines 
relevant to the orofacial tissues in vitro as no published studies have examined the 
effect of these topical NMs. 
Methods 
Cellular viability was measured using alamarBlue®, testing cumulative and specific 
time-point effects of NMs on human skin keratinocytes and oral keratinocytes. 
Effects of the NMs on cell counts were investigated by CCK-8 assay. Drug 
concentrations released from NM orabase pastes after 30 min incubation were 
measured by High-Performance Liquid Chromatography. Using these clinical 
concentrations, morphological changes and cytokine expression were investigated 
using Scanning Electron Microscopy (SEM) and Human Inflammatory Antibody Array 
(AAH) respectively.  
Results 
Cumulative and specific time-point viability and cell count methods revealed that 
Amitriptyline caused a significant decrease in cellular viability and counts in both cell 
lines. Carbamazepine also had significant effects after long-term exposure and at 
higher concentrations, whilst Gabapentin had little demonstrable effect. SEM 
confirmed the cytotoxicity of Amitriptyline, whilst AAH revealed no significant 
changes in cytokine expression following Amitriptyline, Carbamazepine or 
Gabapentin exposure compared with control. 
Conclusions  
The results raise concerns about the safety of topical Amitriptyline as it was cytotoxic 
to skin and oral keratinocytes in both exposure-times and concentrations, whilst 
Carbamazepine was cytotoxic only at high concentrations and after longer exposure-
times and Gabapentin had no demonstrable effects. 
 
Introduction 
Orofacial pain (OFP) is “pain perceived in the face and/or oral cavity caused by 
diseases or disorders of regional structures, by dysfunction of the nervous system, or 
through referral from distant sources” (1). The pathophysiology of persistent OFP is 
varied, but includes neuropathy (2) which can be due to macro or microscopic 
trauma, a disorder, or a disease affecting the trigeminal nerve (3). There are several 
persistent OFP conditions thought to be of neuropathic origin including Persistent 
Dento-Alveolar Pain disorder (PDAP) and Trigeminal Neuralgia (4, 5). Neuropathic 
pain affecting the trigeminal region is known to exert significant impacts on 
individual’s daily lives (6) and following root canal treatment or extraction PDAP is 
thought to occur in 1.6% (7) of cases while trigeminal neuralgia is thought to occur in 
12.7 per 100,000 people (8).  
 
Contemporary evidence-based management of neuropathic pain suggests 
sequential phases of treatment according to the primary diagnosis, efficacy, and side 
effect profile of the medication(s) employed (9). Core classes of medications 
recommended for their efficacy in neuropathic (orofacial) pain are antidepressants 
and anticonvulsants with evidence of their efficacy largely being derived from studies 
focussing on neuropathic pain elsewhere in the body (10). Management of 
neuropathic OFP follows this evidence base, but one of the disadvantages of this 
approach is the necessity to deliver medication, such as antidepressants and 
anticonvulsants, systemically. This route of administration has concomitant side 
effects that are known to affect patient’s adherence to drug regimens especially in 
neuropathic OFP (6). As opposed to systemic administration, topical administration 
of medication may help improve drug delivery to the site of need and also the side-
effect profile of the medication; thereby potentially improving adherence to and 
efficacy of therapy (11). This approach has already shown promise in neuropathies 
outside the orofacial region using medications, such as capsaicin and lignocaine 
patches (12). Sporadic reports of clinical experience employing compounded, 
topical, forms of antidepressants and anticonvulsants (neuromodulatory medication 
[NM]) in neuropathic OFP have emerged in the literature with largely promising 
results (13, 14). The analgesic effect of NMs attributed to peripheral targets, 
Amitriptyline has  a blocking effect on ion gated channels (Na+, Ca++ and K+ 
channels), along with NMDA-receptors and modification of adenosine-receptors 
functions (15-17). Carbamazepine and Gabapentin affinity to block sodium channels 
and calcium subunit (α2δ-1) respectively made them as adjunctive analgesics in 
chronic pain conditions topically, and systemically (15, 18). 
While hepatic, renal, and neuronal tissue cytotoxicity testing has been conducted for 
the systemic administration of NMs, there are no such data for their topical 
application to orofacial tissues or thoroughly investigation of the inflammatory profile 
including cytokine expression except clinical notes (19) following topical application. 
The effect of NMs exposure on cytokine expression has been investigated following 
systemic administration and in vitro studies. The exposure or treatment was 
generally found to be associated with suppression of specific pro-inflammatory 
cytokines (IL-1 and TNF-α), in addition to over expression of anti-inflammatory 
cytokine (IL-10). Carbamazepine exposure and treatment was associated with the 
over expression of the following groups of cytokines: IL-2, IL-5, IL-6 and IL-10 (20-
25) . 
This study investigates the effects of three NMs (Amitriptyline, Carbamazepine and 
Gabapentin) on the relevant oral and skin cell-line models and provides preliminary 
data on drug release from common compounded formulations of these drugs in vitro.
Materials and Methods 
Four groups of experiments were conducted as part of this paper: 
1) Cell viability and median lethal dose calculations.  
2) Cell count experiments. 
3) Drug release and cellular morphology experiments. 
4) Cytokine expression experiments. 
The NMs included and their concentrations were decided after a literature search 
(13, 14), and an informal survey of the international members of the University of 
California, Los Angeles (UCLA) OFP list-serve about the more common 
compounded medications used in neuropathic OFP. The only exceptions to this were 
the cellular morphology and cytokine expression experiments, which used 
concentrations determined from the drug release experiment. 
Keratinocyte non-cancer cell lines were utilised in this study as representative of the 
target orofacial tissues for topical NMs. For more comparative reproducible results, 
the use of cell lines has been approved in cytotoxicity and dental biocompatibility 
investigations (26, 27). The cell lines employed were: immortalized skin 
keratinocytes (HaCat) (28) and immortalized keratinocyte cell line (OKF6-TERT1) 
from oral mucosa (29). 
Preparation of drug solutions 
Pure Amitriptyline hydrochloride (AMI), Carbamazepine (CBZ) and Gabapentin 
(GAB) were obtained from Sigma-Aldrich, UK. Amitriptyline and Gabapentin were 
dissolved in sterile deionized water to stock concentrations of 63.7 mM and 29.1 mM 
respectively, before further dilution in fresh culture media to the working 
concentrations of 200 µM and 1.8 mM, and 150 µM and 5.54 mM respectively. 
Carbamazepine was dissolved in 100% ethanol to a stock concentration of 84.6 mM 
before further dilution in fresh culture medium to two final working solutions of 100µM 
and 1.7 mM (Table 1, outlines the equivalent clinical concentrations of these 
laboratory values). The final concentration of ethanol was <2% in the final working 
solutions and this concentration of ethanol alone did not affect the viability of any cell 
line. For antibody array experiments, serum free media were used to prepare the 
drug solutions.  
Cell Culture 
Immortalized HaCat cells (passage 67) and OKF6-TERT1 cells (passage 7) were 
maintained and passaged as described previously (29, 30). 
1. Cellular viability and medial lethal dose:  
AlamarBlue® (AbD Serotec, Oxford, UK) was used to investigate the effect of NMs 
on cell viability in vitro. This test works by measuring the colour change from blue to 
pink as a result of Resazurin’s chemical reduction, in response to cellular metabolic 
activities during cellular growth and multiplication. This colour change was measured 
by absorbance at a wavelength of 570/600nm. 
Experiments examined the: (a) cumulative effect of NMs on cellular viability, and (b) 
the effect of NMs observed at specific time points of cellular exposure. 
Median lethal dose (LD50) was calculated using absorbance values obtained by the 
alamarBlue® method, using semi-log graph paper for all three drugs and for both 
exposure methods (cumulative and specific time points), applying manufacturer 
instructions. 
a: Cumulative NMs effect: HaCat and OKF6-TERT1 cells were seeded at densities 
of 1×10⁴ and 2×10⁴ cells/well respectively, in 96-well plates with fresh culture media 
to a final volume of 200µl per well. Cells were incubated at 37°C overnight to ensure 
cell attachment. The media were then replaced with 200µl of previously prepared 
media containing pure drug solution at different concentrations of Amitriptyline, 
Gabapentin or Carbamazepine in media plus 10% (v/v) alamarBlue®. After 
incubation, the absorbance was measured after 30min, 1h, 2h, 4h and 24h exposure 
using a plate reader (Synergy HT, BioTek, Winooski, VT) at two wavelengths 
(570/600)nm. 
b: Effect of NMs at specific time points: HaCat and OKF6-TERT1 cells were seeded 
at densities of 1×10⁴ and 2×10⁴ cells/well respectively in 96-well plates containing 
fresh culture media up to a volume of 100µl per well. Cells were incubated at 37°C 
overnight before media replacement with 100µl of previously prepared media 
containing pure drug solution at the different low and high concentrations of 
Amitriptyline, Gabapentin or Carbamazepine. After incubation for 30min and 24h the 
effects of the NM’s effect were stopped by washing the cells in Phosphate Buffed 
Saline (PBS) before further incubation with 100µl of fresh media, plus 10% (v/v) 
alamarBlue®. Absorbance was measured after 4h incubation. 
2. Cell counting assay:  The CCK-8 assay (Dojindo Laboratories, Kumamoto, 
Japan) is based on cellular activity, specifically dehydrogenases and mitochondrial 
activity, resulting in reduction of Tetrazolium salts (yellow) to Formazan (orange) that 
can be quantified. The CCK-8 assay was used to investigate changes in cultured cell 
counts, in response to exposure the NMs. HaCat and OKF6-TERT1 cells were 
seeded and treated as before alongside a range of control cells seeded at different 
cell densities to establish a calibration curve. After incubation for 30min and 24h, the 
effect of the NM was again stopped by washing the cells in PBS. Cells were then 
incubated with 100µl fresh media plus 10% (v/v) CCK-8 reagent. Absorbance was 
measured after incubation for 150min using a plate reader (BioTek, Winooski, VT) at 
450nm wavelength. 
3. Drug release and cellular morphology experiments  
A sterile Orabase® paste without additives (ConvaTec, Deeside, UK) was mixed with 
the required amount of the pure medication powder using a doubling up technique 
(31) in order to prepare NMs at clinically published concentrations (13, 14). 
Approximately 2g from the resultant Amitriptyline (2% w/v, 63.7mM), Gabapentin 
(4% w/v, 169.3mM) and Carbamazepine (4% w/v, 233.6mM) topical paste was then 
used to coat the inner walls of a 6 well-plate. The wells were then filled with 6ml of 
culture medium. Thirty minutes of incubation were used in both the drug release and 
cellular morphology experiments as it was felt this was a realistic time for a topical 
medication to be present in the oral cavity once applied to the buccal mucosa. After 
30min incubation, the media were aspirated and sent for High-Performance Liquid 
Chromatography (HPLC) analysis to establish the concentration of drug released 
from the topical paste. Replicate samples were analysed (Cardiff Toxicology 
Laboratories, Llandough hospital, Penarth, UK). 
Cellular morphology 
HaCat and OKF6-TERT1 cells were seeded on coverslips at 1×10⁵ and 2×10⁵ per 
well respectively in a 12 well plate with 2ml of media as the final volume per well. 
After overnight incubation, the media were discarded and replaced with 2ml of new 
media alone (control) or media containing one of the NMs at a concentration that 
reflected the HPLC findings in the drug release experiment. After 30min incubation, 
media were then aspirated and stored at -20°C to be used later in Antibody Array 
Assay. The cover slips were fixed and processed for SEM as described previously 
(32).  
4. Cytokine expression 
An exploratory Human Inflammation Antibody Array C1 (RayBiotech®, Norcross, 
USA) was used to investigate a number of cytokines expressed in duplicate samples 
of conditioned media that had been collected from cells exposed to NMs for 30min. 
The cytokines present on the array were Eotaxin-1, Eotaxin-2, G-CSF, GM-CSF, 
IFN-γ, IL-1α, IL1-β, IL-2, IL-3, IL-4, IL-6, IL-7, IL-8, IL-10, IL-11, IL-12p40, IL-12p70, 
IL-13, I-309, TIMP-2. Membranes were treated following the manufacturer’s 
instructions before being developed on highly sensitive Amersham Hyperfilm ECL for 
2 min. 
Statistical analysis: Simple descriptive statistics and one-way ANOVA followed by 
Bonferroni post hoc tests were conducted in SPSS version 22 (SPSS Inc., Chicago, 
IL).  
Results 
1. Cell Viability 
A: Cumulative NMs effect: In vitro effects of pure NMs on HaCat cellular viability are 
shown in Figure 1. HaCat cellular viability was significantly reduced by both low 
(200µM) and high (1.8mM) Amitriptyline concentrations compared to untreated 
controls (p<0.05). Carbamazepine exposure significantly reduced cellular viability 
only at high (1.7mM) concentrations and after 2h of exposure (p<0.05), while 
Gabapentin significant reduced viability only at high (5.54mM) concentrations 
(p<0.05). HaCat cell exposure to low concentrations of Carbamazepine and 
Gabapentin at all time points produced no significant changes compared with 
controls (p>0.05).  
 
In oral keratinocyte cells, (OKF6-TERT1, Figure 2) significant reductions in viability 
(p<0.05) were observed after exposure to  Amitriptyline at low (200µM) 
concentrations for 4h and high (1.8mM) concentrations for 2h. Similar observations 
were found for Carbamazepine after exposure to high (1.7mM) concentrations for 4h. 
Neither concentration of Gabapentin significantly affected cellular viability compared 
with controls (p>0.05). 
 
The median lethal dose (LD50 ) of Amitriptyline in HaCat cells (Figure S1, in the 
supplementary materials) was 512µM and 186µM at 30min and 24h respectively. For 
Carbamazepine, the LD50 value for HaCat cells was 398 µM after 24h exposure 
(Figure S2). Gabapentin had no LD50 effect (Figure S3). In OKF6-TERT1 cells, the 
only LD50 for Amitriptyline was 630µM after 24h exposure. 
b: Effect of NMs at specific time points: Exposure of HaCat cells to 200µM and 
1.8mM Amitriptyline  for 30min and 24h significantly reduced their viability compared 
with controls (p<0.05). Exposure to high concentrations of Carbamazepine (1.7mM) 
for 24h also resulted in a significant loss of viability (p<0.05) (Figure 3). Gabapentin 
showed no significant effect on cellular viability compared with control.  
Short-term (30 min) exposure of OKF6-TERT1 cells to Amitriptyline, Carbamazepine 
and Gabapentin at all concentrations significantly decreased cellular viability 
compared with untreated controls(p<0.05, Figure 4). Both Amitriptyline 
concentrations and high concentrations of Carbamazepine and Gabapentin 
significantly reduced the viability of OKF6-TERT1 cells after longer exposure (24h), 
(p<0.05, Figure 4). 
The only LD50 value was for Amitriptyline exposure at 30min (141µM), (Figures S4-
S6). 
2. Cell counting assay:  
Using the calibration curve the estimated number of HaCat cells was less than 5,000 
after 30min exposure to Amitriptyline at low (200µM) and high (1.8mM) 
concentrations. At the 24h time point, the cell count was less than 1,000 (Figure S7). 
Exposure to low (100µM) and high (1.7mM) concentrations of Carbamazepine for 30 
min caused a similar reduction in cell counts. However, after 24h exposure to 100µM 
Carbamazepine, cell counts were similar to controls. High concentration 
Carbamazepine reduced cell counts to less than 1000 (Figure S8). Gabapentin 
exposure for 30 mins had no significant effects on cell counts, but after 24h exposure 
to 150µM Gabapentin, cell counts were less than 10,000 (Figure S9). 
In OKF6-TERT1 cells, exposure to low concentration Amitriptyline (200µM) for 30 
min reduced cell counts by half, to 10,000   (Figure S10). High concentration 
Amitriptyline (1.8mM) reduced the cell count to <2,000 after 30 mins, whilst after 
exposure to high and low concentrations for 24h cell counts reduced to less than 
200.  
Exposure to Carbamazepine at both low (150µM) and high (1.7mM) concentration 
for 30min had no effects on cell counts. After 24h exposure to both concentrations, 
cell counts dropped to 15,000 (Figure S11). Exposure to Gabapentin at low (150µM) 
and high (5.45mM) concentrations for 30 min or 24h had no effects on cell counts 
(Figure S12). 
3. Drug release experiment and cellular morphology experiments 
HPLC analysis of the aspirated media after 30min incubation with Orabase paste 
containing Amitriptyline (2% w/v), Carbamazepine (4% w/v), and Gabapentin (4% 
w/v), demonstrated transfer of 226µM, 123.9µM and 5.54mM drug concentrations 
respectively in the media.  
SEM revealed considerable changes in the cellular attachment and morphology of 
HaCat and OKF6-TERT1 cells exposed to 226µM Amitriptyline only (Figure 5). 
4. Global cytokine expression 
There were no significant differences in the expression of twenty different 
inflammatory cytokines between controls and both cell lines after 30min exposure to 
the NMs at the concentrations determined by the drug release experiment. 
Discussion 
Neuropathic OFP can be challenging to manage because of the limited number of 
proven interventions available (33). This difficulty and patient frustration with side 
effects (6) may have driven the move towards topical compounded NMs, based upon 
a reasonable hypothesis about the advantages this route of administration may offer 
(34). However, compounded formulations are not without their problems (35) and 
represent a challenge and a responsibility to the prescriber from a safety and 
efficacy perspective (36).  
Prior to commencing any Phase I clinical trial for a new drug, the U.S. Food and 
Drug Administration (FDA) requires detailed preclinical data for that drug that 
includes cytotoxicity (37). In these in vitro cytotoxicity studies, the typical tissue 
regarding systemically administered drugs are target, metabolism and excretion 
tissues. In the case of topical NMs that are applied on orofacial tissues in higher 
concentrations, however these drugs are already approved systemic medications, it 
is necessary to examine their toxic effects on these tissues as changing the rout of 
administration suggested different pharmacokinetic and pharmacodynamics 
reactions(38).  
This in vitro study tested the effect of three NMs on cellular viability, count and 
morphology in addition to inflammatory response. Regarding viability, two exposure 
methods were used: cumulative drug and specific time-point effects.  
There are limited reports in the literature regarding the in vitro cytotoxicity of 
Amitriptyline, but those that are present demonstrate cytotoxicity in both human and 
animal cell lines attributed to different mechanisms including: mitochondrial 
dysfunction; increased production of reactive oxygen species leading to alteration in 
cellular metabolism and permeability and elevated intracellular oxidative stress (25, 
39). In the current study, Amitriptyline reduced cellular viability and cell counts in 
both cell lines at all concentrations and all time points and SEM examination 
confirmed these findings. The cytotoxicity of Amitriptyline was also demonstrated in 
its LD50 values, which were low in both cell lines and after short exposure times.  
The apoptotic and anti-proliferative effects of Carbamazepine have been 
investigated mainly in neurone and glial cell culture, using much lower 
concentrations than presented here (40, 41). Comparing to Amitriptyline, in the 
current study, Carbamazepine was less cytotoxic in both cell lines, and major 
changes in viability only occurred at high concentrations and longer exposure times. 
SEM revealed no major changes in cellular morphology and attachment. The LD50 
values were also confirmatory as they were calculable only after a cumulative 
exposure of 24h, which is not clinically realistic for the topical application of a gel in 
the oral cavity.  
Gabapentin appeared to be the least cytotoxic of the agents tested. Only a high 
concentration and long exposure time (24h) caused a demonstrable reduction in 
cellular viability. A LD50 was not calculable. This is consistent with previous few 
reports in literature (42), that employed lower concentrations of Gabapentin in vitro 
than the current study. 
In our experiments, there was a very low level of detected cytokine expression, with 
all NMs, and the cytokine expressions did not differ to control. This could be due to 
the short exposure time (30min) used and the method of measuring cytokine 
expression was employed, because it allowed multiple cytokines to be analysed at 
the same time. 
The major limitation of this study is its use of a monolayer culture, which is 
conceivably more susceptible to the cytotoxic effects of medications than a more 
complex three-dimensional tissue model. However, the laboratory concentrations of 
NMs used in viability and counting experiments were much lower than those used in 
clinical practice and yet still demonstrated cytotoxicity. The concentrations employed 
also mirrored the ranges of drug concentrations used in the drug release experiment.  
Within the limits of this investigation, the clinical implications for future topical in vivo 
NM trials are that low Gabapentin and Carbamazepine concentrations are unlikely to 
adversely affect oral mucosa and skin. However, if Amitriptyline is to be trialled in 
vivo, short exposure times and very low concentrations with careful clinical 
assessment of skin and oral mucosa after repeated exposure are advisable. 
Conclusions 
Viability, cell counting, and SEM experiments revealed that Amitriptyline was 
cytotoxic to both oral and skin keratinocyte cells in vitro. Gabapentin and 
Carbamazepine affected cellular viability to a lesser extent, even at high 
concentrations and long exposures. Caution should be exercised in the topical 
application of Amitriptyline to skin and oral mucosa. 
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Table 1: Laboratory and equivalent clinical concentrations of Amitriptyline (AMI), 
Carbamazepine (CBZ) and Gabapentin (GAB). 
Neuromodulatory 
medications 
(NMs) 
Low concentration High concentration 
Laboratory 
concentration 
(µM) 
Equivalent 
clinical 
concentration 
(%) 
Laboratory 
concentration 
(mM) 
Equivalent 
clinical 
concentration 
(%) 
AMI 200 0.006 1.8 0.05 
CBZ 100 0.002 1.7 0.04 
GAB 150 0.002 5.54 0.09 
 
 
 
  
Figure Legends: 
Figure 1: Viability of HaCat cells exposed to Amitriptyline (AMI), Carbamazepine (CBZ) and 
Gabapentin (GAB), measured using alamarBlue®. Mean values + SEM (n=8) are shown for each 
experiment. Compared with untreated control cells (black dotted line) by one-way ANOVA 
followed by Bonferroni’s post hoc test, * p<0.05. 
 
Figure 2: Viability of OKF6-TERT1 cells exposed to Amitriptyline (AMI), Carbamazepine (CBZ) 
and Gabapentin (GAB), measured using alamarBlue®. Mean values + SEM (n=8) are shown for 
each experiment. Compared with untreated control cells (black dotted line) by one-way ANOVA 
followed by Bonferroni’s post hoc test, * p<0.05. 
 
Figure 3: Viability of HaCat cells exposed to Amitriptyline (AMI), Carbamazepine (CBZ) and 
Gabapentin (GAB) at 30min and 24h time points, measured using alamarBlue®. Mean values + 
SEM (n=6) are shown for each experiment. Compared with untreated control cells (black 
dotted line) by one-way ANOVA followed by Bonferroni’s post hoc test, * p<0.05. 
 
Figure 4: Viability of OKF6-TERT1 cells exposed to Amitriptyline (AMI), Carbamazepine (CBZ) 
and Gabapentin (GAB) at 30min and 24h time points, measured using alamarBlue®. Mean 
values + SEM (n=6) are shown for each experiment. Compared with untreated control cells 
(black dotted line) by one-way ANOVA followed by Bonferroni’s post hoc test, * p<0.05. 
 
Figure 5: SEM images at 100 X magnification of OKF6-TERT1 and HaCat cells after 30min 
exposure to NMs at concentrations determined by HPLC. 
